GlassScriptPhysician profile
Mark John Eledio Eribal
NPI 1134739907
$2,989.91
in general payments reported to CMS, 2019-2025
17 companies · $896 in 2025
The $896 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $414 · 2023: $779 · 2024: $704 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,184 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,183.66 |
| Education | $194.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,035.87 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $540.00 | 2023-2025 | Empaveli |
| Janssen Biotech, INC. | $323.84 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Daiichi Sankyo INC. | $257.10 | 2021-2025 | Injectafer, Vanflyta, Enhertu |
| Amgen INC. | $125.00 | 2021 | |
| Seagen INC. | $124.98 | 2022 | |
| Abbvie INC. | $123.88 | 2025 | |
| Incyte Corporation | $99.95 | 2024 | |
| Genzyme Corporation | $83.76 | 2022 | |
| Celgene Corporation | $82.80 | 2022-2023 | Pomalyst |
| Pharmaessentia USA Corporation | $55.91 | 2025 | Besremi |
| Karyopharm Therapeutics INC. | $32.51 | 2022 | |
| Pfizer INC. | $26.55 | 2022 | |
| Astellas Pharma US INC | $23.66 | 2025 | Vyloy |
| Alexion Pharmaceuticals, INC. | $20.26 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18.43 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.41 | 2024 | Alunbrig |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark John Eribal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.